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The concept of risk factors has become an integral part of 
clinical assessment and decision making for patients at risk of 
either a first or a recurrent cardiovascular event. Unfortu- 
nately, risk factors are often misinterpreted aseither necessary 
or sufficient causes of disease. People without risk factors also 
develop diseases; they are simply less likely to do so than those 
with risk factors. Risk factors represent associations, which 
may or may not be causal. 
This task force addresses the conceptual basis for interpret- 
ing risk factors by answering a series of pertinent questions. 
1. What is a risk factor? A risk factor is a factor whose 
presence is associated with an increased likelihood that disease 
will develop at a later time. A broad range of factors influence 
risk, from personal characteristics to laboratory measurements. 
The term "associated" does not necessarily connote causation. 
Not everyone with a risk factor is destined to develop the 
disease. Further, the risk may be very small or very high in 
absolute terms. "Later in time" could be short or long term. 
2. How arc risk factors categorized? Prevention can be 
primary or secondary. Primary prevention i volves intervention 
before the onset of disease. Secondary prevention involves 
intervention after the onset of disease. Most factors associated 
with the first episode or manifestation are also predictive of 
recurrent events. Although the risk for a recurrent event is 
often dominated by indicators of the severity of the first event, 
such as left ventricular dysfunction, other risk factors still play 
an important role and merit continued attention. 
Risk factors may be modifiable or nonmodifiable. Smoking, 
hypertension and hyperlipidemia are examples of the former, 
whereas family history, age and gender are examples of the 
latter. This characterization has obvious clinical implications 
since only the former can be targeted for preventive measures, 
but the presence of nonmodifiable risk factors may affect the 
degree of attention accorded to the modification of other risk 
factors. For example, a positive family history may warrant 
greater intensity of risk factor management because of the 
greater hazard for coronary disease events. 
3. How can an association be interpreted? An association 
between a risk factor and a disease may be present or absent 
due to chance alone or a lack of power. Similarly, the associ- 
ation may be present or absent due to systematic errors in 
selection or observation. For example, comparing patients 
from a hospital setting with subjects from the general popula- 
tion may create or obscure associations that are due to 
selection rather than the disease. Finally, an association may 
be present or absent due to confounding, which results from 
the presence of another factor that artificially creates or 
obscures the relationship between the factor and the outcome 
of interest. In a study of smoking and heart disease, without 
adjustment for age, the true hazard could be underestimated 
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because smokers are younger than nonsmokers, given that age 
is such a powerful determinant of risk. 
Risk factors involve associations, and their interpretation is 
complicated by the fact that the term "association" is a 
statistical claim that may or may not involve causation. Once a 
valid association is established, the next question is whether 
the association is causal. Causation is best judged based on 
evidence from randomized clinical trials. However, most risk 
factors are never evaluated in this fashion, not only because 
many are nonmodifiable, but also because it would be uneth- 
ical to expose people to substances that are potentially harm- 
ful. Specific toxic effects of smoking have only been examined 
through direct exposure in animal experiments. In humans, this 
causative relationship may be evaluated indirectly in random- 
ized trials by withdrawal of exposure. For example, the benefit 
of smoking cessation has been tested in clinical trials. Such 
so-called withdrawal trials have several methodologic limitations. 
In the absence of evidence from clinical trials, observational 
studies can provide evidence supporting the causative associ- 
ation between risk factors and disease. The likelihood of 
causation is strengthened under the following conditions: 
1. The stronger the association, the more convincing is the 
evidence that the relationship s causal. Strong associations are 
less likely to be the result of uncontrolled confounding. 
2. Studies demonstrate hat the exposure to the risk factor 
antedates the onset of disease. This criterion can be difficult o 
establish for many chronic onditions. Periods of induction and 
latency must be considered. 
3. The association is shown to be dose-dependent. A good 
example is cigarette smoking. A 2-pack/day smoker has a 
higher isk of developing an acute myocardial infarction than a 
1-pack/day smoker, who has a higher isk than a person who 
does not smoke. 
4. The relationship is consistently demonstrated under 
diverse circumstances, either in various populations or using 
different measurement methodologies. 
5. The association isbiologically plausible. In other words, 
the connection is supported by knowledge linking the factor 
and the disease. 
6. The association is specific, that is, the risk factor is 
associated with a particular disease. This criterion is difficult o 
meet for conditions that have a multifactorial genesis. 
4. How are risk factors assessed and identified? Risk 
factors can be assessed in studies where patients are enrolled 
based on their exposure, as in cohort studies, or presence or 
absence of disease, as in case-control studies. For a prospective 
cohort study, the starting point is the assessment of the 
presumed risk factors. This approach elps to ensure compa- 
rable assessment and allows one to confirm that exposure 
precedes the onset of disease. The cohort is followed from that 
point, and the development of subsequent clinical outcomes of 
interest, such as acute myocardial infarction or stroke, are 
recorded. The statistical associations between the presumed 
risk factors and the outcome are typically determined in 
cardiovascular studies after several years. However, as indi- 
cated in the definition of a risk factor, the association can be 
determined for any period of follow-up. It is possible that the 
strength of an association may be influenced by the length of 
the observation period. 
The cohort can be any defined population. Observational 
studies are often population-based, but they may also include 
either patients admitted to hospitals with a specific diagnosis or 
patients randomized to the placebo group in a clinical trial. 
Obviously, the interpretation and the generalizability of the 
findings depend on the criteria for selection of the cohort. 
Findings are generalizable to the population from which the 
cohort was sampled. Generalizing beyond the specific popula- 
tion sample can be problematic f there are important biologic 
differences between populations, such as gender and age. 
Differences among populations may explain some of the 
observed ifferences in the predictive value of a risk factor in 
various tudies. 
It is important to realize that any observed or reported 
association, for example, a risk ratio or risk difference, is an 
estimate of the true association. There is a degree of variability 
around the estimate that is quantified by the 95% confidence 
interval. The confidence interval simply represents he range 
within which the true value is likely to lie. There is a direct 
relationship between the 95% confidence interval and the p 
value. Specifically, if the estimate of no association (i.e., 1.0 for 
a risk ratio and zero for a risk difference) lies outside the 95% 
confidence interval, then the probability (p < 0.05) that the 
association is due to chance is less than 5%, and by convention 
we call the finding "statistically significant." On the other hand, 
if the null point lies within the 95% confidence interval, then 
p > 0.05, and we accept by convention that the finding is not 
statistically significant. The confidence interval provides addi- 
tional information. Specifically, the width of the confidence 
interval provides an assessment of the estimate and places 
boundaries on its likely minimum and maximum values. A 
relative risk of 2.0 with a confidence interval of 1.8 to 2.4 gives 
a much more precise estimate of the true effect than a 
confidence interval of 1.2 to 3.0, despite the fact that both are 
statistically significant. In the latter case, the true effect may be 
as small as a 20% or as large as a threefold increase in risk. 
Wide confidence intervals are almost always due to small 
sample size or difficulty in measurement. For a finding of no 
association, a narrow confidence interval will add support o the 
belief that there is no true increased risk. Whereas a wide 
confidence interval suggests hat the data are compatible with a 
true effect, but that the sample size was too small to have 
adequate statistical power to exclude chance as a likely explana- 
tion. 
5. How should clinicians interpret risk factors? Risk is 
usually assessed in one of two ways. The risk ratio is estimated 
by dividing the rate of disease for those with a factor of interest 
by the rate of those without he factor. This is usually reported 
as a relative risk in prospective studies and as an odds ratio in 
case-control studies. When the outcome is a rare event, the 
odds ratio and relative risk are very similar. In addition, risk 
can also be calculated by subtracting the rate in those without 
the factor of interest from the rate in those with it. This risk 
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difference is usually called attributable risk. For coronary heart 
disease risk factors, the absolute attributable risk increases 
often markedly with age, whereas the relative risk may, in fact, 
decrease. For example, the relative risk of stroke due to 
hypertension is smaller in the elderly than in middle age, but 
among 100 treated patients, older patients will receive more 
absolute benefits from treatment than middle-aged adults. 
Nonetheless, for common and serious diseases, such as heart 
disease and stroke, a small alteration in relative risk will have 
an important clinical and public health impact. 
The strength of one risk factor in the presence of another 
may be greater than the sum of the strengths of the individual 
factors. For example, women of childbearing age who use 
oral contraceptives have about twice the risk of myocardial 
infarction than nonusers. In addition, women of childbearing 
age who smoke have about 13 times the risk of myocardial 
infarction than nonsmokers. However, women of childbearing 
age who both use the pill and smoke have about 40 times the 
risk of myocardial infarction compared to those who do 
neither. Finally, given the risk and prevalence of oral contra- 
ceptives and cigarette smoking in the U.S. population, oral 
contraceptives accounts for almost 400 deaths each year, 
whereas cigarette smoking accounts for 400,000 deaths each 
year. 
Points to remember:. 
1. In assessing a risk factor, one can reasonably conclude 
the presence or absence of a valid statistical association, having 
considered the possible roles of chance, bias and confounding 
as alternative explanations. 
2. In making a judgment about a cause and effect relation- 
ship, one must consider not simply the results of a single study, 
but the totality of the evidence from all studies. Furthermore, 
criteria that increase belief in causality include strength of 
association, temporal sequence, dose-response, consistency, 
biologic plausibility and specificity. 
3. Risk can be measured in relative or absolute terms. 
Whereas high relative risks increase the likelihood of a cause/ 
effect relationship, high absolute attributable risks identify the 
public health consequences and value of treatment. 
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Understanding the concept of risk and risk factors is central to 
the evaluation of the hazard for coronary disease events and 
essential for appropriate clinical decision making with respect 
to the management of specific factors associated with coronary 
disease risk. The notion of risk is not new, but the idea that 
specific factors serve as markers of the level of risk has arisen 
relatively recently, largely as a result of population-based 
studies such as the Framingham Heart Study. Critical to our 
